Dashboard
Madrigal Pharmaceuticals, Inc.
MDGLNASDAQFor informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Universal block
Live market data + trailing fundamentals.
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 16Trial initiationClinicalTrials.gov
Phase 4 trial (NCT07848191) recruiting for Rezdiffra with concomitant therapies in adults with MASH and F2-F3 fibrosis.
- Nov 12Trial initiationClinicalTrials.gov
Phase 1 trial NCT07830758 of resmetirom in MASH and HFpEF updated to recruiting status.
- Nov 6Ownership changeSEC
Form 4 insider transaction filing on 2026-11-06.
- Nov 6Ownership changeSEC
Form 4 insider transaction filing reported.
- Nov 3Financial resultsSEC
Madrigal Pharmaceuticals filed 8-K (items 2.02, 9.01) disclosing results of operations and financial condition.
- Oct 16Trial initiationClinicalTrials.gov
Phase 1 trial of resmetirom in MASH and HFpEF initiated and recruiting (NCT07830758)
- Oct 16Trial initiationClinicalTrials.gov
Phase 4 trial (NCT07848191) of Rezdiffra with concomitant therapies in MASH patients with F2-F3 fibrosis now recruiting.
- Sep 29Trial initiationClinicalTrials.gov
Madrigal plans Phase 4 trial of Rezdiffra with concomitant therapies in MASH patients with F2-F3 fibrosis (NCT07848191, not yet recruiting)
- Sep 21Trial initiationClinicalTrials.gov
Phase 1 trial initiation of resmetirom in MASH patients with HFpEF (NCT07830758, not yet recruiting)
- Sep 11Ownership changeSEC
Form 4 insider transaction filing dated 2026-09-11.
- Sep 11Trial initiationClinicalTrials.gov
Madrigal initiates Phase 2 trial of resmetirom in children and adolescents with MASH (NCT07763015, recruiting).
- Aug 26Trial initiationClinicalTrials.gov
Madrigal initiates Phase 2 trial of resmetirom in post-liver transplant MASH patients (NCT07335601, recruiting).
- Aug 20Ownership changeSEC
Form 4 filing for insider transaction at Madrigal Pharmaceuticals.
- Aug 18Ownership changeSEC
SEC Form 4 insider transaction filing.
- Aug 13Trial initiationClinicalTrials.gov
Madrigal initiates Phase 2 trial of resmetirom in children and adolescents with MASH (NCT07763015), status not yet recruiting.
- Aug 12LeadershipSEC
8-K filed with items 5.02, 7.01, 9.01 covering officer/director changes and related disclosures.
- Jul 31Trial initiationClinicalTrials.gov
Madrigal initiates Phase 2 trial (NCT07335601) of resmetirom in post-liver transplant MASH patients; status recruiting.
- Jul 30Financial resultsSEC
8-K filing (items 2.02, 9.01) reporting results of operations and financial condition.
- Jul 20Ownership changeSEC
Form 4 insider transaction filing
- Jul 8OtherClinicalTrials.gov
Phase 3 MAESTRO-NASH-OUTCOMES trial (NCT05500222) for resmetirom in NASH cirrhosis status updated to ACTIVE_NOT_RECRUITING.
Not financial advice — research and opinion only. Disclosures